# US 2013/0156849 A1 · Modified nucleoside, nucleotide, and nucleic acid compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156849 A1
- Document ID: US20130156849A1
- Status: Published application
- Kind: A1
- Application number: 13/714,458
- Filed: 2012-12-14
- Published: 2013-06-20
- Earliest claimed: 2011-12-16
- Assignees: Moderna Therapeutics, Inc.
- Inventors: Antonin de Fougerolles; Kristy M. Wood; Sayda M. Elbashir; Noubar B. Afeyan; Pedro Valencia; Jason P. Schrum
- Web page: https://patentgrep.com/patent/US20130156849A1

## CPC

- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/7115: Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
- A61K 38/4833: {Thrombin (3.4.21.5)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 2/00: Peptides of undefined number of amino acids; Derivatives thereof
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12N 15/67: General methods for enhancing the expression
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

## Claims

### Claim 1

A method of producing a polypeptide of interest in a mammalian cell or tissue, the method comprising, contacting said mammalian cell or tissue with a formulation comprising a modified mRNA encoding the polypeptide of interest, wherein the formulation is selected from the group consisting of nanoparticles, poly(lactic-co-glycolic acid) (PLGA) microspheres, lipidoid, lipoplex, liposome, polymers, carbohydrates (including simple sugars), cationic lipids, fibrin gel, fibrin hydrogel, fibrin glue, fibrin sealant, fibrinogen, thrombin, rapidly eliminated lipid nanoparticles (reLNPs) and combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the modified mRNA comprises a purified IVT transcript.

### Claim 3 (depends on 1)

The method of claim 1, wherein the formulation comprising the modified mRNA is a nanoparticle and wherein said nanoparticle comprises at least one lipid.

### Claim 4 (depends on 3)

The method of claim 3, wherein the lipid is selected from the group consisting of DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG and PEGylated lipids.

### Claim 5 (depends on 3)

The method of claim 3, wherein the lipid is cationic lipid.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cationic lipid is selected from the group consisting of DLin-DMA, DLin-K-DMA, DLin-MC3-DMA, DLin-KC2-DMA and DODMA.

### Claim 7 (depends on 3)

The method of claim 3, wherein the lipid to modified mRNA weight ratio is between 10:1, and 30:1.

### Claim 8 (depends on 7)

The method of claim 7, wherein the mean size of the nanoparticle formulation comprising the modified mRNA is between 60-225 nm.

### Claim 9 (depends on 8)

The method of claim 8, wherein the PDI of the nanoparticle formulation comprising the modified mRNA is between 0.03 and 0.15.

### Claim 10 (depends on 3)

The method of claim 3, wherein the zeta potential of the lipid is from −10 to +10 at a pH of 7.4.

### Claim 11 (depends on 7)

The method of claim 7, wherein the nanoparticle formulation comprising the modified mRNA further comprises a fusogenic lipid, cholesterol, and a PEG lipid.

### Claim 12 (depends on 11)

The method of claim 11, wherein the nanoparticle formulation comprising the modified mRNA has a molar ratio of 50:10:38.5:1.5-3.0 (Cationic Lipid: fusogenic lipid: Cholesterol: PEG lipid).

### Claim 13 (depends on 12)

The method of claim 12, wherein the PEG lipid is selected from PEG-c-DOMG and PEG-DMG and the fusogenic lipid is DSPC.

### Claim 14 (depends on 1)

The method of claim 1, wherein contacting is through the use of a device selected from the group consisting of syringe pump, internal osmotic pump and external osmotic pump.

### Claim 15 (depends on 1)

The method of claim 1, wherein the formulation comprising the modified mRNA is a poly(lactic-co-glycolic acid) (PLGA) microsphere.

### Claim 16 (depends on 15)

The method of claim 15, wherein microspheres of the PLGA microsphere formulation comprising the modified mRNA are between 4 and 20 μm in size.

### Claim 17 (depends on 15)

The method of claim 15, wherein the PLGA microsphere formulation comprising the modified mRNA release less than 50% of the modified mRNA in a 48 hour time period.

### Claim 18 (depends on 15)

The method of claim 15, wherein the PLGA microsphere formulation comprising the modified mRNA is stable in serum.

### Claim 19 (depends on 18)

The method of claim 18, wherein the stability is determined relative to unformulated modified mRNA in 90% serum.

### Claim 20 (depends on 15)

The method of claim 15, wherein the loading weight percent is at least 0.05%, at least 0.1%, at least 0.2%, at least 0.3%, or at least 0.4%.

### Claim 21 (depends on 15)

The method of claim 15, wherein the encapsulation efficiency of the modified mRNA in the PLGA microspheres is at least 50%.

### Claim 22 (depends on 15)

The method of claim 15, wherein the encapsulation efficiency of the modified mRNA in the PLGA microspheres is at least 70%.

### Claim 23 (depends on 15)

The method of claim 15, wherein the encapsulation efficiency of the modified mRNA in the PLGA microspheres is at least 90%.

### Claim 24 (depends on 15)

The method of claim 15, wherein the encapsulation efficiency of the modified mRNA in the PLGA microspheres is at least 97%.

### Claim 25 (depends on 11)

The method of claim 11, wherein contacting said mammalian cells or tissues occurs via a route of administration selected from the group consisting of intravenous, intramuscular, intravitreal, intrathecal, intratumoral, pulmonary, and subcutaneous.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polypeptide of interest is detectable in the serum for up to 72 hours after contacting at levels higher than the levels prior to contacting.

### Claim 27 (depends on 26)

The method of claim 26, wherein the polypeptide of interest is detectable in the serum of female subjects at levels greater than in the serum of male subjects.

### Claim 28 (depends on 1)

The method of claim 1, wherein the formulation further comprises a second modified mRNA.

### Claim 29 (depends on 28)

The method of claim 28, wherein the formulation further comprises a third modified mRNA.

### Claim 30 (depends on 1)

The method of claim 1, wherein the formulation comprising the modified mRNA comprises a rapidly eliminated lipid nanoparticle.

### Claim 31 (depends on 30)

The method of claim 30, wherein the rapidly eliminated lipid nanoparticle comprises an reLNP lipid, fusogenic lipid, cholesterol and a PEG lipid at a molar ratio of 50:10:38.5:1.5 (reLNP Lipid: Fusogenic lipid: Cholesterol: PEG lipid).

### Claim 32 (depends on 31)

The method of claim 31, wherein the fusogenic lipid is DSPC and the PEG lipid is PEG-c-DOMG.

### Claim 33 (depends on 31)

The method of claim 31 wherein the reLNP lipid is selected from the group consisting of DLin-DMA with an internal ester, DLin-DMA with a terminal ester, DLin-MC3-DMA- with an internal ester, and DLin-MC3-DMA with a terminal ester.

### Claim 34 (depends on 30)

The method of claim 30, wherein in the total lipid to modified mRNA weight ratio is between 10:1 and 30:1.

### Claim 35 (depends on 1)

The method of claim 1, wherein contacting occurs via injection using a split dosing schedule.

### Claim 36 (depends on 35)

The method of claim 35, wherein the injection is made to the tissue selected from the group consisting of intradermal space, epidermis, subcutaneous tissue, and muscle.

### Claim 37 (depends on 1)

The method of claim 1, wherein the formulation comprising the modified mRNA comprises a fibrin sealant.

### Claim 38 (depends on 1)

The method of claim 1, wherein the formulation comprising the modified mRNA comprises a lipidoid and wherein the lipid is selected from the group consisting of C12-200 and 98N12-5.

### Claim 39 (depends on 1)

The method of claim 1, wherein the formulation comprising the modified mRNA is a polymer and said polymer is coated, covered, surrounded, enclosed or comprises a layer of hydrogel or surgical sealant.

### Claim 40 (depends on 39)

The method of claim 39, wherein the polymer is selected from the group consisting of PLGA, ethylene vinyl acetate, poloxamer and GELSITE®.

### Claim 41 (depends on 40)

The method of claim 40, further comprising an additional layer of polymer, hydrogel or surgical sealant.

### Claim 42 (depends on 2)

The method of claim 2, wherein the modified mRNA comprises at least one 5′ terminal cap selected from the group consisting of Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2′ fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.

### Claim 43 (depends on 42)

The method of claim 42, wherein the 5′ terminal cap is Cap1.

### Claim 44 (depends on 43)

The method of claim 43, wherein the modified mRNA comprises at least two modifications.

### Claim 45 (depends on 44)

The method of claim 44, wherein the at least two modifications are independently selected from the group consisting of 5-methylcytidine, pseudouridine, and 1-methyl-pseudouridine.

### Claim 46

A method of producing a polypeptide of interest in a mammalian cell or tissue, the method comprising, contacting said mammalian cell or tissue with a buffer formulation comprising a modified mRNA encoding the polypeptide of interest.

### Claim 47 (depends on 46)

The method of claim 46, wherein the buffer formulation is selected from the group consisting of saline, phosphate buffered saline, and Ringer's lactate.

### Claim 48 (depends on 46)

The method of claim 46, wherein the buffer formulation comprises a calcium concentration of between 1-10 mM.

### Claim 49 (depends on 46)

The method of claim 46, wherein the modified mRNA comprises a purified IVT transcript.

### Claim 50 (depends on 46)

The method of claim 46, wherein contacting said mammalian cells or tissues occurs via a route of administration selected from the group consisting of intravenous, intramuscular, intravitreal, intrathecal, intratumoral, pulmonary, and subcutaneous.

### Claim 51 (depends on 25, 50)

The method of claim 25 or 50, wherein said polypeptide of interest is produced in said cell or tissue in a location systemic from the location of contacting.

### Claim 52 (depends on 51)

The method of claim 51 wherein the route of administration is either via intramuscular or subcutaneous.

### Claim 53 (depends on 3)

The method of claim 3, wherein the lipid nanoparticle formulation is further formulated in a sealant.

### Claim 54 (depends on 53)

The method of claim 53, wherein said sealant is a fibrin sealant.

### Claim 55

A method of producing a pharmacologic effect in a primate comprising contacting said primate with a composition comprising a formulated modified mRNA encoding a polypeptide of interest.

### Claim 56 (depends on 55)

The method of claim 55, wherein the modified mRNA comprises a purified IVT transcript.

### Claim 57 (depends on 56)

The method of claim 56, wherein the formulation is selected from the group consisting of nanoparticles, poly(lactic-co-glycolic acid) (PLGA) microspheres, lipidoid, lipoplex, liposome, polymers, carbohydrates (including simple sugars), cationic lipids, fibrin gel, fibrin hydrogel, fibrin glue, fibrin sealant, fibrinogen, thrombin, rapidly eliminated lipid nanoparticles (reLNPs) and combinations thereof.

### Claim 58 (depends on 57)

The method of claim 57, wherein the pharmacologic effect is greater than the pharmacologic effect associated with a therapeutic agent known to produce said pharmacologic effect.

### Claim 59 (depends on 57)

The method of claim 57, wherein the pharmacologic effect is greater than the pharmacologic effect produced by a composition comprising an unformulated modified mRNA encoding the polypeptide of interest.

### Claim 60 (depends on 57)

The method of claim 57, wherein the pharmacologic effect is greater than the pharmacologic effect produced by a composition comprising a formulated unmodified mRNA encoding the polypeptide of interest.

### Claim 61 (depends on 57)

The method of claim 57, wherein the pharmacologic effect results in a therapeutically effective outcome of a disease, disorder, condition or infection.

### Claim 62 (depends on 61)

The method of claim 61, wherein the pharmacologic effect is selected from the group consisting of a change in cell count, alteration in serum chemistry, alteration of enzyme activity, increase in hemoglobin, and increase in hematocrit.

### Claim 63 (depends on 62)

The method of claim 62, wherein the therapeutically effective outcome is selected from the group consisting of treatment, improvement of one or more symptoms, diagnosis, prevention, and delay of onset.
